Medical evidence on alleged Dupixent cancer risks is mixed, and it comes from real-world data rather than a clear signal in the original phase 2 and 3 trials, where no lymphoma or cutaneous lymphoma cases were reported at approval.
Over time, case reports of dupilumab associated lymphoma have described patients who developed cutaneous T-cell lymphoma (CTCL) or other lymphoid cancers after starting Dupixent, often with skin lesions that initially looked like ordinary atopic dermatitis.
Recent database work, including TriNetX and insurance or health-system cohorts, has reported that some patients with atopic dermatitis receiving dupilumab appear to have a higher relative risk of developing cutaneous lymphoma, with at least one Dermatologic Therapy analysis estimating a several-fold increase in CTCL risk compared to non-users, particularly in older adults and often within about a year of starting therapy.
In contrast, a large TriNetX retrospective cohort study across atopic dermatitis and other type 2 inflammatory diseases found that the underlying conditions themselves carry elevated lymphoma risk, including CTCL and non-Hodgkin lymphoma, and that dupilumab use did not increase lymphoma rates compared to other systemic treatments and may modestly reduce risk in some non-dermatologic groups.
A separate population-based cohort in asthma compared nearly 15,000 patients who initiated dupilumab with more than 730,000 on combination therapy with inhaled corticosteroids and LABA and found that the primary outcome of new-onset lymphoma, especially T-cell and NK-cell lymphomas, was more frequent in the dupilumab group, while secondary outcomes included other malignancies and all-cause mortality.
In that study, dupilumab treatment was associated with higher lymphoma incidence but also significantly lower all-cause mortality, leading the authors to call for long-term surveillance and further research rather than immediate changes in use.
Pharmacovigilance reviews of the FDA’s FAERS database show CTCL is disproportionately reported with dupilumab compared to other cutaneous lymphomas and other malignant neoplasms, and in March 2025 the FDA formally identified CTCL as a potential serious risk and opened a safety review, though it has not concluded that Dupixent causes lymphoma or added a specific cancer warning to the label.
At the same time, narrative reviews and expert groups stress that CTCL often begins as subtle, eczema-like patches caused by abnormal T cells in the skin, so some “dupilumab associated lymphoma” cases may represent unrecognized cancer that was already present and only became obvious after inflammation changed under treatment.
Mechanistic and integrative epidemiology studies explore how IL-4/IL-13 blockade might interact with malignant T cells, but those models remain theoretical and do not yet prove causation.
Taken together, these data suggest a concerning but still unsettled signal: CTCL and related T-cell lymphomas appear more often than expected in certain dupilumab-treated populations, while overall malignancy and mortality patterns are more reassuring.
For patients and clinicians, the practical takeaway is not panic but vigilance, especially for new or changing skin lesions, patches, or tumors that do not behave like typical eczema, and for older adults with late-onset or atypical dermatitis who start Dupixent.
Cutaneous T-Cell Lymphoma (CTCL) And Other T-Cell Lymphomas
Cutaneous T-cell lymphoma (CTCL) is a rare cancer of abnormal T cells that primarily affects the skin, often beginning with red, itchy patches or plaques that can closely resemble chronic eczema.
In the context of dupilumab treatment, recent studies suggest that some adults treated for presumed atopic dermatitis later go on to develop CTCL or related T-cell lymphomas, sometimes within the first year of therapy.
Certain cohort and database studies have reported a higher risk of CTCL in dupilumab-treated eczema patients compared to similar patients who were not exposed to the drug, although researchers continue to debate whether this reflects a true drug effect, unmasking of pre-existing disease, or a mix of both.
At the same time, other malignancies do not appear consistently increased across all Dupixent users, which is why the current concern is focused on CTCL and related T-cell and NK-cell lymphomas rather than a broad, generalized cancer signal.
Key clinical and scientific points about CTCL and other T-cell lymphomas in Dupixent litigation include:
- CTCL often starts with skin-limited lesions that look like stubborn eczema, making early cancer difficult to recognize without targeted biopsies.
- Several case series describe patients whose presumed dermatitis worsened or changed under dupilumab treatment, only to be reclassified as CTCL after repeat biopsies.
- Observational data and registry studies report elevated rates of CTCL in dupilumab-treated atopic dermatitis cohorts when compared to non-dupilumab controls.
- T-cell and NK-cell lymphomas, rather than B-cell lymphomas or solid tumors, account for most of the reported lymphoid cancers in recent studies linking dupilumab and lymphoma risk.
- Expert reviews stress that these findings support a signal that warrants further research and close clinical monitoring, but they do not yet prove that Dupixent universally causes CTCL or other T-cell malignancies.
CTCL Symptoms That Can Look Like Severe Eczema
Cutaneous T-cell lymphoma (CTCL) can carry a potential risk of being mistaken for severe eczema because early lesions often look like the same red, itchy, scaly patches seen in chronic atopic dermatitis.
People with long-standing “eczema” or asthma receiving dupilumab who notice changes in their skin or new systemic symptoms may need closer evaluation, since some CTCL and even related natural killer (NK) cell lymphomas have first appeared in this setting.
CTCL can also cause whole-body symptoms, such as enlarged lymph nodes and unexplained weight loss, that are easy to overlook when attention is focused only on the skin.
Common CTCL symptoms that can look like severe eczema include:
- Red, itchy, scaly patches or plaques that persist for months or years despite standard eczema treatments
- Skin lesions that thicken, form raised plaques, or develop nodules or tumors over time
- Rashes or plaques on unusual or sun-protected areas of the body, especially if they spread or change in appearance
- Areas of skin that change color, become mottled, or develop persistent discoloration not typical of prior eczema flares
- Intense, unrelenting itch that feels different from a person’s usual eczema pattern
- Enlarged lymph nodes in the neck, armpits, or groin
- Unexplained weight loss, fevers, or night sweats along with worsening skin disease
Misdiagnosis, Delayed Diagnosis, And Disease Progression
Misdiagnosis is common in cutaneous T-cell lymphoma because early lesions resemble stubborn eczema, so many patients spend years cycling through topical steroids, systemic drugs, and even dupilumab without anyone suspecting cancer.
When CTCL is treated as routine dermatitis instead of a malignancy of abnormal T cells, biopsies may be delayed, interpreted as nonspecific inflammation, or never repeated after the initial result.
This kind of delayed diagnosis allows disease to progress from flat patches to thicker plaques and tumors, and in some cases to involve lymph nodes, blood, and internal organs.
In patients on Dupixent, persistent or changing skin disease is sometimes attributed to “refractory eczema” or a partial drug response instead of prompting a new workup, which can add months of lost time.
By the time CTCL or another T-cell lymphoma is recognized, people may require more aggressive treatment, including multi-agent chemotherapy, radiation, or advanced systemic therapies.
From a legal perspective, this sequence of misdiagnosis, delayed diagnosis, and disease progression is central to allegations that inadequate warnings and limited clinical guidance left patients and doctors unprepared to consider lymphoma in the setting of ongoing skin symptoms.
For families weighing a Dupixent cancer claim, reconstructing this timeline through dermatology notes, pathology reports, and imaging is critical to understanding how long CTCL was present before it was finally identified.
